Berberine Promotes OATP1B1 Expression and Rosuvastatin Uptake by Inducing Nuclear Translocation of FXR and LXRα

Mingyi Liu†, Dandan Zhu†, Jinhua Wen², Wei Ding¹, Shibo Huang¹, Chunhua Xia¹, Hong Zhang¹ and Yuqing Xiong*¹

¹ Clinical Pharmacology Institute, Nanchang University, Nanchang, China, ² Department of Pharmacy, First Affiliated Hospital of Nanchang University, Nanchang, China

Berberine, a quinoline alkaloid, can be used in combination with statins to enhance hypolipidemic effects and reduce the dose and side effects of statins. The hypolipidemic effects of statins in the liver are mainly regulated by organic anion transporting polypeptides (OATPs), and the expression of OATPs is regulated by nuclear receptors. Berberine has been reported to affect nuclear receptors. However, whether berberine affects the uptake of statins by regulating nuclear receptor-mediated expression of OATPs remains to be determined. The aim of this study was to investigate the effects of berberine on the expression of OATP1B1 in HepG2 and explore the underlying mechanism. In HepG2 cells, 10–50 μM berberine significantly increased the uptake of rosuvastatin by inducing the expression of OATP1B1 mRNA and protein. Dual-Luciferase reporter assay showed that luciferase activity of hFXR and hLXRα activated OATP1B1 promoter was increased by 2.5–50 μM berberine in a concentration-dependent manner, with half-maximal effective concentration (EC50) of 12.19 ± 0.86 and 32.15 ± 2.32 μM, respectively. In addition, after silencing FXR or LXRα by small interfering RNA (siRNA), berberine-induced OATP1B1 expression was significantly attenuated. Western blot analysis of FXR and LXRα protein levels in the cytoplasm and nucleus of HepG2 cells after treatment with berberine showed that berberine induced nuclear translocation and activation of FXR and LXRα. In conclusion, berberine-induced nuclear translocation of FXR and LXRα could activate OATP1B1 promoter, resulting in enhanced expression of OATP1B1 and increased uptake of rosuvastatin.

Keywords: berberine, OATP1B1, FXR, LXRα, rosuvastatin

INTRODUCTION

Statins have been widely used as lipid-lowering drugs because they are inhibitors for hydroxyl methylglutaryl coenzyme A (HMG-CoA) reductase. The combination therapy of statins with bile acid sequestrants, niacin, or ezetimibe have significantly improved efficacy in the treatment of hyperlipidemia (Knapp et al., 2001; Wolfe et al., 2001; Robinson and Davidson, 2006; Huijgen et al.,...
2010). However, combination therapy have the possibility to increase adverse effects such as muscle toxicity and myopathy, which may be associated with drug interactions mediated by organic anion transporting polypeptide (OATP) transporters (Steffa et al., 2002; Shitara and Sugiyama, 2006; Kitamura et al., 2008; Kunze et al., 2014).

Pregnane X receptor (PXR), constitutive androgen receptor (CAR), farnesoid X receptor (FXR), and liver X receptor α (LXRα) are members of constitutive and ligand-activated nuclear receptor superfamily and play a crucial role in regulating target genes involved in drug metabolism and transport (Urquhart et al., 2007; Staudinger et al., 2013). FXR and LXRα have been characterized as transcriptional factors which regulate the expression of OATP1B1 (Meyer Zu Schwabedissen et al., 2010). Rifampicin significantly increases the expression of OATP1B1 protein and mRNA in hepatocytes by activating PXR (Jigorel et al., 2006).

Berberine is a compound isolated from traditional Chinese medicines and exerts a variety of pharmacological effects such as anti-diabetes, immunoregulation, anti-hypertension, anti-arrhythmia, and lipid-lowering (Lau et al., 2001; Kong et al., 2004; Kong et al., 2009; Gu et al., 2015; Montes et al., 2019; Neag et al., 2018; Belwal et al., 2020.). In addition, berberine regulates metabolic enzymes and transporters to affect the absorption, distribution and metabolism of endogenous and exogenous substances in vivo. Berberine increased the blood concentration of cyclosporine A in renal transplanted patients by inhibiting CYP3A4 (Wu et al., 2005). Moreover, berberine can regulate the absorption and metabolism of dextromethorphan, losartan, and midazolam in healthy human by suppressing the activity of CYP2D6, 2C9, and 3A4 (Guo et al., 2012). Berberine-activated LXRα increased the expression of ABCA1 transporter and reduced the accumulation of low-density lipoprotein cholesterol (LDL-c) in macrophages to prevent the formation of foam cells (Lee et al., 2010). Berberine-disrupted STAT5 signaling promoted Ntcp/NTCP expression, resulting in enhanced bile acid uptake (Bu et al., 2017). In addition, berberine-activated RXRα/FXR and RXRα/LXR heterodimers enhanced luciferase activity of FXRE and LXRE (Ruan et al., 2017). Recently, combination of statins and berberine has been clinically used to treat hyperlipidemia. Kong et al. demonstrated that combined use of simvastatin and berberine significantly reduced LDL-c levels in rats and hyperlipidemia patients and adverse effects compared to monotherapy (Kong et al., 2008). The combination of berberine and simvastatin remarkably attenuated adverse effects such as rhabdomyolysis and improved the efficacy and safety of treatment (Bei-Bei et al., 2009; Li et al., 2019). Therefore, we speculated that berberine could induce the expression of OATP1B1 transporter through nuclear receptors and boosts the uptake of statins by hepatocytes, thereby improving the lipid-lowering efficacy in combination treatment. Notably, rosuvastatin is not metabolized by CYP450 but is transported by OATP (White, 2002). Therefore, in this study we used rosuvastatin to avoid the interference by CYP450 and used HepG2 cell as the model to investigate the effects of berberine on the expression of OATP1B1 and explore the underlying mechanisms.

**MATERIALS AND METHODS**

**Chemicals**

Berberine (purity 98.0%), atorvastatin [internal standard (IS) for rosuvastatin, purity 95.3%], and rosuvastatin (purity 97.6%) were obtained from the National Institutes for Food and Drug Control Products (Beijing, China). GW4064 (purity 99.80%) and GW3965 (purity 99.09%) were purchased from SelleckChem (Houston, TX, USA). Rifampicin (RIF, purity 97.0%) was purchased from Sigma-Aldrich (St. Louis, MO, USA). CITCO (purity 98.0%) was purchased from APEXBio (Beijing, China). FXR, LXRα, OATP1B1, and GAPDH oligonucleotide primers were synthesized by Sangon Biotech Co., Ltd (Shanghai, China). The Dual-Luciferase reporter assay system was purchased from Promega (Madison, WI, USA). Lipofectamine 3000 were purchased from Thermo Fisher Scientific (New York, USA). Rabbit polyclonal antibodies to OATP1B1 (catalog: DF4534), LXRα (catalog: DF6864) and GAPDH (catalog: AF0911) were purchased from Affinity Biosciences (Cincinnati, OH, USA). Rabbit polyclonal antibody to FXR (catalog: ab235094) was purchased from Abcam (Abram, Cambridge, MA). HANK’s balanced salt mixture (supplemented with Mg2+ and Ca2+) and 1 mol/L HEPES were supplied by Solarbio (Beijing, China). All other chemicals were of analytical grade and were commercially available. Berberine, GW3964 and GW4064 were all dissolved in dimethylsulfoxide (DMSO) to prepare stock solutions of 10 mM. The working solutions were obtained by diluting the stock solutions with DMEM medium and final concentrations of DMSO were no more than 0.1%.

**Plasmids and Small Interfering RNAs**

The pTracer-hFXR, pTracer-hLXRα, and empty pTracer-CMV2 vector were purchased from Majie Biotech (NanTong, China). The pGL3-OATP1B1 reporter plasmid containing LXRα response element (−128 to +53 bp) and FXR response element (−3040 to −4070 bp) fragment of the SLC01B1 5′-UTR was constructed by Majie Biotech (NanTong, China). (Meyer Zu Schwabedissen et al., 2010) The small interfering nas (siRNAs) against hFXR (5′-GAGGAUGCCUCACGAAAUA-3′) and hLXRα (5′-AUCTCAATGATGCTGAGTT-3′) and negative control scramble siRNA were purchased from Majie Biotech (NanTong, China).

**Cell Culture**

The human liver carcinoma cell line HepG2 was provided by Novo Biotechnology (Shanghai, China) and cultured in Dulbecco’s modified Eagle medium (DMEM, Solarbio Co., Ltd, Beijing, China) supplemented with 10% fetal bovine serum (FBS, Biological Industries, Israel) as described previously (Zhong et al., 2018). Cells were cultured toLe-80% confluence and then treated with the chemicals for 24 h, and cells treated with...
0.1% DMSO (generally considered noncytotoxic) were used as the blank control.

**Real-Time PCR**

Total RNA was isolated from HepG2 cells using EasySpin cell RNA extraction kit (Aidlab Biotechnologies Co., Ltd, Beijing, China) following the manufacturer’s instruction. RNA (1.5 μg) was first reverse-transcribed into cDNA using Transcriptor First-strand cDNA Synthesis Kit (TransGen Biotech, Beijing, China), and real-time PCR was performed with Premix Ex Taq™ Probe qPCR (TaKaRa Biotech, Kyoto, Japan) following the manufacturer’s instructions. The following primers were used: OATP1B1, 5′-ACCTGTAGTACGGTGAGAT-3′ (forward) and 5′-ACCTGTAGACTAGGATGTAGAT-3′ (reverse); FXR, 5′-TCAGCCCAACATCCCATC-3′ (forward) and 5′-CCTGTGACAAGAAAGCGG-3′ (reverse); LXRα, 5′-CCACTGCCCATGGGACA-CCT-3′ (forward) and 5′-GTGTCCTCTCCTCTGCGGCTTC-3′ (reverse); GAPDH, 5′-CAGGGCTGCTTTTAACTCTGGT-3′ (forward) and 5′-GATTTTGGAGGGA-TCTGCTGCT-3′ (reverse). The data were calculated according to the comparative ΔΔCT method and presented as relative fold of the control.

**Western Blot Analysis**

Cells were lysed with RIPA buffer (Applygen Gene Technology Co., Ltd, Beijing, China), and the nuclear and cytoplasmic proteins were separated and extracted using a nuclear and cytoplasmic extraction kit (Boster, Wuhan, China) according to the manufacturer’s instructions. Protein concentrations were quantified with BCA protein assay kit (Vazyme Biotech, Nanjing, China). Proteins (20 μg/sample) were separated using 10% SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membranes. Subsequently, the membranes were blocked for 2 h with 5% skim milk and then incubated overnight at 4°C with primary antibodies. The membranes were washed in TBS and then incubated with horseradish peroxidase-conjugated anti-rabbit or anti-rat IgG antibody (Santa Cruz, CA, USA) for 1 h at room temperature. GAPDH and Lamin B1 were used as loading controls. The bands were detected using a Bio-Rad ChemiDoc XRS imaging system (Bio-Rad Laboratories).

**Rosuvastatin Uptake Assay**

Rosuvastatin uptake assay in HepG2 cells was performed as previously described (Li et al., 2012). Briefly, the cells were seeded at 2 × 10^5/well into 24-well plates and cultured for 24 h, and then treated with a medium containing berberine or a blank control (0.1% DMSO) at 37°C for 24 h. In the uptake experiments, cells were washed three times with HBS–HEPES (99:1) uptake buffer at 37°C, and then the cells were incubated for 10 min in uptake buffer containing 20 μM rosuvastatin. After the incubation, the buffer was quickly aspirated, the cells were washed three times with ice-cold HBSS–HEPES buffer, and repeatedly thawed three times at −80°C and room temperature. Finally, 100 μl cell lysate was spiked with 20 μl IS (10 ng/ml atorvastatin), and 200 μl methanol was added. The mixture was then vortexed for 1 min and centrifuged at 10,000g for 10 min, with an aliquot (10 μl) automatically injected into the LC-MS/MS system for analysis, and protein content was determined by BCA method. Three independent experiments were performed in triplicates.

**Quantification of Rosuvastatin by LC-MS/MS**

The concentration of rosuvastatin in cells was determined by LC-MS/MS system consisted of Shimadzu LC-20AB pumps (Shimadzu Corporation, Kyoto, Japan) and an AB SCIEX API 4000 mass spectrometer (Applied Biosystems/SCIEX, Foster, CA, USA). Data acquisition was performed using Analyst 1.6.1 software (AB SCIEX). Chromatographic separation was achieved on a Luna C18 column (50 × 2.0 mm i.d., 5 μm; Phenomenex Technologies). The mobile phase consisted of 10-mM ammonium formate (A) and acetonitrile (B) using a gradient elution of 40-90% B at 0.0–1.0 min, 90%–90% B at 1.0–2.5 min, and 40%–40% B at 2.51–3.5 min. The flow rate was 0.4 ml/min, the operating temperature was 25°C.

Samples were ionized utilizing an electrospray-ionization probe in the positive-ion mode, and quantification was performed using the multiple-reaction monitoring (MRM) method, with the precursor-to-product transition being m/z 482.3→258.2 for rosuvastatin and m/z 559.2→440.0 for atorvastatin (IS). Nitrogen was used as the curtain and auxiliary gas, and air was used as the nebulizer gas under the following conditions: curtain gas, 40 psi; ion-spray voltage, 5500 V; nebulizer gas, 50 psi; auxiliary gas, 50 psi; and turbo temperature, 500°C. The collision energy (CE) was 45 V for rosuvastatin and 28V for atorvastatin, and the declustering potential (DP) was 118 V for rosuvastatin and 100 V for atorvastatin.

**Dual Luciferase Assay**

pTracer-hFXR, pTracer-hLXRα, and empty pTracer-CMV2 vector were purchased from Maijie Biotech (Nanjing, China). The pGL3-OATP1B1 vector was prepared as described (Meyer Zu Schwabedissen et al., 2010) containing LXR response element (−128 to +53 bp) and FXR response element (−3,040 to −4,070 bp) fragment of the SLCO1B1 5′-UTR, and empty plasmid pGL3-Basic, internal reference Renilla luciferase plasmid pRL-TK were purchased from Maijie Biotech. Corresponding plasmids were transfected into HepG2 cells with Lipofectamine 3000 transfection reagent following the manufacturer’s instructions. Finally, the cells were harvested and cell lysates were assayed for firefly activities normalized against the activities of co-transfected renilla luciferase using a dual-luciferase kit (Promega).

**RNA Interference**

The siRNA against hFXR or hLXRα and negative control scramble siRNA were purchased from Maijie Biotech (Nanjong, China). siFXR (5′-GAGGAGUGCCUA-GGAAUA-3′) or siLXRα (5′-AACCTCAATGATGCTGAGTT-3′) was transfected into HepG2 cells at the final concentration of 50 nmol/L. The knockdown efficiency was detected by Western blot analysis.
Statistical Analysis
The data from three independent experiments were presented as mean ± standard deviation (mean ± SD), and one-way ANOVA was used to determine the differences among the groups using GraphPad Prism 5.0. p < 0.05 indicated that the differences were significant.

RESULTS
Effect of Berberine on OATP1B1 Expression in HepG2 Cells
To investigate the effects of berberine on the expression of OATP1B1, HepG2 cells were treated with a series of concentrations of berberine (5, 10, 25, and 50 μM) for 24 h, or treated with 25 μM berberine for a series of time (6, 12, 24, and 48 h). Real-time PCR showed that berberine significantly upregulated OATP1B1 mRNA levels in a concentration and time-dependent manner (Figures 1A, B). Western blot analysis showed that 10–50 μM berberine enhanced the expression of OATP1B1 protein in a concentration-dependent manner after 24-h treatment (Figures 1C, D).

Berberine Increased Rosuvastatin Uptake in HepG 2 Cells
To investigate the effects of berberine on OATP1B1 transport function, the time- and concentration-dependent uptake assays were conducted, and uptake kinetic parameters were examined in a series concentration or time point (data not shown). The HPLC-MS-MS method for the determination of rosuvastatin was validated with selectivity, precision, accuracy, extract recovery, and matrix effect (Supplementary Figure 1). The uptake of rosuvastatin was linear with time over the first 10 min, and the Km (Michaelis constant) was determined to be 21.50 ± 1.77 μM, thus we performed the specific rosuvastatin uptake test under the condition of 20 μM and 10 min. After treatment with increasing concentrations (2, 5, 10, 25, and 50 μM) of berberine for 24 h, the uptake of rosuvastatin was increased 1.24-fold (5 μM berberine-treated), 1.42-fold (10 μM berberine-treated), 1.78-fold (25 μM berberine-treated), and 1.93-fold (50 μM berberine-treated)
compared to control, respectively (Figure 2A). The half-maximal effective concentration (EC$_{50}$) value was measured to be 19.01 ± 1.21 µM (Figure 2B).

**Berberine Enhanced FXR and LXRα Mediated Activation of OATP1B1 Promoter**

HepG2 cells were treated with 10 µM of nuclear receptor ligands including rifampicin (PXR ligand), CITCO (CAR ligand), GW4064 (FXR ligand), or GW3965 (LXRα ligand) for 24 h. PCR and Western blot analysis showed that only GW3965 (a specific LXRα agonist) and GW4064 (a specific FXR agonist) markedly upregulated the expression of OATP1B1 mRNA and protein (Figures 3A, B).

Next we performed dual luciferase reporter assay to investigate the potency of berberine on activating transcriptional activity of LXRα and FXR on OATP1B1 promoter. As shown in Figure 4A, luciferase activity significantly increased after treatment with 25 µM berberine or/and 10 µM corresponding ligands. Meanwhile, the EC$_{50}$ value was 12.19 ± 0.86 µM in HepG2-hFXR-OATP1B1-luc cells (Figure 4B), and the EC$_{50}$ value was 32.15 ± 2.32 µM in HepG2-hLXRα-OATP1B1-luc cells (Figure 4C), while the EC$_{50}$ in the two cell lines were 2.56 ± 0.21 and 2.37 ± 0.36 µM, respectively, after GW4064 and GW3965 treatment. These data suggest that berberine could improve hFXR or hLXRα-mediated activation of OATP1B1 luciferase activity in a concentration-dependent manner.

**Berberine Enhanced FXR and LXRα Induced Expression of OATP1B1 Protein and Transport Function**

To further investigate the potency of LXRα and FXR activated by berberine on regulating OATP1B1 expression, HepG2 cell models with silenced or induced FXR and LXRα activities were

---

**FIGURE 2** | Berberine enhanced rosvastatin uptake in HepG2 cells. (A, B) Rosuvastatin uptake assay was conducted in HepG2 cells treated with increasing concentrations (2, 5, 10, 25, and 50 µM) of berberine for 24 h. The concentrations of rosvastatin were determined by HPLC-MS/MS. DMSO (0.1%) was used as the negative control. Data are expressed as mean ± SD of triplicate independent experiments, *P < 0.05, ***P < 0.001 compared to the control.

**FIGURE 3** | Effects of diverse nuclear receptors activators on OATP1B1 expression in HepG2 cells. HepG2 cells were treated with 10 µM GW3965, 10 µM rifampin, 10 µM GW4064, or 10 µM CITCO for 24 h, OATP1B1 expression was determined by real-time PCR (A) and Western blot analysis (B). DMSO (0.1%) was used as the negative control. Data are expressed as mean ± SD from triplicate independent experiments, ***P < 0.001 compared to the control.
constructed. First, Western blot analysis confirmed that transfection of siRNA-hFXR or siRNA-hLXRα into HepG2 cells significantly reduced FXR and LXRα protein levels compared to control group (Figures 5A, C). Subsequently, HepG2 cells were treated with berberine, GW4064, GW3965, or/and FXR/LXRα siRNAs. As shown in Figures 5B, D, the induction of OATP1B1 expression by GW4064 and GW3965 was significantly increased by berberine, while FXR or LXRα siRNA eliminated the upregulation of OATP1B1 by berberine. Furthermore, berberine, GW4064 and GW3965 significantly increased the uptake of rosuvastatin by OATP1B1, but knockdown of FXR or LXRα significantly reduced berberine stimulated rosuvastatin uptake by OATP1B1 (Figure 5E). These results indicate that FXR and LXRα participate in the upregulation of OATP1B1 expression by berberine.

**Berberine Induced Nuclear Translocation of FXR and LXRα**

Previous studies reported that nuclear receptors such as FXR and LXRα regulate the expression of target genes after ligand-induced nuclear translocation (Lee et al., 2010; Xu et al., 2016). Therefore, we investigated the effect of berberine on the expression and distribution of FXR and LXRα in HepG2 cells. PCR analysis showed that berberine significantly increased FXR mRNA expression in a concentration-dependent manner (Figure 6A). Consistently, Western blot analysis showed that berberine upregulated the expression of FXR protein in HepG2 cells, except that the induction of FXR protein by berberine was attenuated slightly at the highest dose of 50 μM (Figure 6B). However, berberine had no significantly effect on the expression of LXRα at both mRNA and protein levels (Figures 6D, E). Subsequently, cytoplasmic proteins and nuclear proteins were isolated and Western blot analysis showed that nuclear FXR and LXRα protein levels increased significantly after treatment with berberine for 24 h, while cytoplasmic FXR and LXRα protein levels decreased slightly (Figures 6C, F). These results indicate that berberine could promote nuclear translocation of FXR and LXRα.

**DISCUSSION**

In this study, we provide the first evidence that berberine enhanced FXR and LXRα mediated upregulation of OATP1B1 expression, resulting in enhanced uptake of the substrate rosuvastatin in HepG2 cells, which may be responsible for improved lipid-lowering efficacy in combination with statins.

Berberine is a new type of hypolipidemic drug widely used with favorable clinical efficacy and safety (Kong et al., 2004; Kong et al., 2009). Studies have reported that the combination of berberine with simvastatin can significantly enhance the hypolipidemic efficacy in patients and rats with hyperlipidemia, reduce the dose of statins, and lower the risk of adverse reactions (Bei-Bei et al., 2009; Kong et al., 2009; Li et al., 2019). Notably, we found that rosuvastatin had rapid uptake in HepG2 cells, this may be explained by that rosuvastatin is mainly transported by OATP1B1 and OATP1B3, which are highly expressed in the liver (Hagenbuch and Meier, 2003). Furthermore, we showed that berberine upregulated the expression of OATP1B1 transporter at both mRNA and protein levels in HepG2 cells, which could promote rosuvastatin uptake in HepG2 cells.

FXR and LXRα are widely involved in the regulation of transporters expression in vivo. Ligand-activated FXR can upregulate BSEP transcription, inhibit NTCP transcription or induce PLTP and CYP7A1 expression to promote bili acid secretion, suppress uptake of bili acid in the liver or increase cholesterol metabolism (Mak et al., 2002). LXRα regulates the metabolism of bili acids and cholesterol in the liver by regulating target genes such as CYP7, ABC transporter ABCA1, and lipoprotein lipase (Peet et al., 1998; Schmitz and Langmann, 2001). It has been reported that nuclear receptors FXR and LXRα...
can act on OATP1B1 promoter to regulate the expression (Meyer Zu Schwabedissen et al., 2010). Our study demonstrated that berberine regulated the expression of OATP1B1 by activating FXR and LXRα. This finding was confirmed by Dual-Luciferase reporter assay. The results indicated that berberine had stronger induction on hFXR-mediated transcriptional activation of OATP1B1 than on hLXRα, but the effect was weaker than classical agonists GW4064 and GW3965. However, the combination of berberine and the corresponding agonists can further improve the expression of target proteins. Silencing FXR or LXRα by siRNA dramatically diminished the upregulation of OATP1B1 expression by berberine. These results confirmed that FXR and LXRα mediate the effects of berberine on the upregulation of OATP1B1 expression.

However, the underlying mechanism by which berberine activates FXR and LXRα in HepG2 cells is unclear. LXRα and
FIGURE 6 | Effects of berberine on FXR and LXRα expression and distribution in HepG2 cells. HepG2 cells were treated with increasing concentrations of berberine (10, 25, and 50 μM) for 24 h. FXR (A) and LXRα (D) mRNA levels were measured by PCR; protein levels were measured by Western blot (B, E). The nuclear and cytoplasmic FXR (C) and LXRα (F) protein levels were quantified by Western blot. The determination of mRNA and protein were normalized to GAPDH, nuclear and cytoplasmic protein was normalized to Lamin B1 and GAPDH, respectively. DMSO (0.1%) was used as the negative control. Data are expressed as mean ± SD of triplicate independent experiments,*P < 0.05, **P < 0.01, ***P < 0.001 compared to the control.
FXR have been identified as critical nuclear receptors which bind to the promoters of target genes to regulate transcriptional activity of downstream target genes after ligand-activated nuclear translocation (Meyer Zu Schwabedissen et al., 2010; Xu et al., 2016; Zhou et al., 2016). In this study we found that berberine promoted nuclear translocation and activation of FXR and LXRα, similar to other Chinese herbal medicines such as ginkgolide b (Zhou et al., 2016) and dihydroartemisinin (Xu et al., 2016). In addition, berberine significantly increased the expression of FXR protein and mRNA at 10 and 25 μM, but only moderately upregulated the expression of FXR protein at 50 μM, while the mRNA expression was still significantly upregulated, suggesting that FXR may be subjected to a series of post-transcriptional regulations, such as phosphorylation, acetylation, and glycosylation (Chang, 2009; Sugatani et al., 2014).

Although statins are known as HMG-CoA reductase inhibitors, previous study suggested that berberine inhibited HMG-CoA reductase activity via increased phosphorylation of HMG-CoA reductase, leading to reduced hepatic cholesterol level (Wu et al., 2011). In addition, recent reports showed that berberine could inhibit lipogenesis by targeting sterol regulatory element-binding protein (SREBP) related signaling (Yunxin et al., 2019; Zhu et al., 2019). Therefore, further studies are needed to demonstrate that berberine and statins in combination can inhibit SREBP signaling and HMG-Co reductase activity to achieve enhanced hypolipidemic effects.

In summary, our results suggest that berberine upregulates the expression of OATP1B1 in HepG2 cells by inducing nuclear translocation of FXR and LXRα, which then activate the expression of OATP1B1 and increase the uptake of rosuvastatin.

DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the article Supplementary Material.

AUTHOR CONTRIBUTIONS
YX, HZ, and CX participated in study design. ML, DZ, and WD conducted the experiments and analyzed the data. JW and SH contributed to the writing of the manuscript.

FUNDING
This work was supported by the Natural Science Foundation of China (No. 81673506).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.00375/full#supplementary-material

REFERENCES
Bei-Bei, Z., Jing, W. E. I., Jian-Dong, J., He-He, G., and Rui-Sheng, Z. (2009). The therapeutic effects of combination of simvastatin with berberine on the patients with hyperlipemia. Acta Universitatis Med. Nanjing 29, 1493–1497.
Belwal, T., Bishit, A., Devkota, H.P., Ullah, H., Khan, H., Bhatt, I.D., et al. (2020). hytopharmacology and clinical updates of Berberis species against diabetes and other metabolic diseases. Front. Pharmacol. 11, 41. doi: 10.3389/fphar.2020.00041
Bu, P., Le, Y., Zhang, Y., Zhang, Y., and Cheng, X. (2017). Berberine-induced inactivation of signal transducer and activator of transcription 5 signaling promotes male-specific expression of a bile acid uptake transporter. J. Biol. Chem. 292, 4602–4613. doi: 10.1074/jbc.M116.757567
Chang, T. K. H. (2009). Activation of pregnane x receptor (pxr) and constitutive androstane receptor (car) by herbal medicines. AAPS J. 11, 590–601. doi: 10.1208/s12248-009-9135-y
Gu, S., Cao, B., Sun, R., Tang, Y., Paletta, J. L., Wu, X.-L., et al. (2015). A metabonomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine. Mol. Biosyst. 11, 463–474. doi: 10.1039/c4mb00509g
Guo, Y., Chen, Y., Tan, Z.-R., Klaassen, C. D., and Zhou, H.-H. (2012). Repeated administration of berberine inhibits cytochromes p450 in humans. Eur. J. Clin. Pharmacol. 68, 213–217. doi: 10.1007/s00228-011-1198-2
Hagenbuch, B., and Meier, P. J. (2003). The superfamily of organic anion transporting polypeptides. Biochim. Et Biophys. Acta-Enzyme-Biomembranes 1609, 1–18. doi: 10.1016/S0005-2736(02)00633-8
Huigen, R., Abbink, E. J., Bruckert, E., Stalenhoef, A. F. H., Imholz, P. B. M., Durrington, P. N., et al. (2010). Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: A 12-week, multicenter, randomized, double-blind, controlled trial. Clin. Ther. 32, 615–625. doi: 10.1016/j.clinthera.2010.04.014
Jigoder, E., Le Vee, M., Bousier-Neyret, C., Parmentier, Y., and Fardel, O. (2006). Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Disposition 34, 1756–1763. doi: 10.1124/dmd.106.010033
Kitamura, S., Maeda, K., Wang, Y., and Sugiyama, Y. (2008). Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Disposition 36, 2014–2023. doi: 10.1124/dmd.108.021410
Knapp, H. H., Schrott, H., Ma, P., Knopp, R., Chin, B., Gaziano, J. M., et al. (2001). Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. 110, 352–360. doi: 10.1016/s0002-9343(01)00638-6
Kong, W. J., Wei, J., Abidi, P., Lin, M. H., Inaba, S., Li, C., et al. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 10, 1344–1351. doi: 10.1038/nm1135
Kong, W., Wei, J., Zou, Z., Wang, Y., Song, D., You, X., et al. (2008). Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 57, 1029–1037. doi: 10.1016/j.metabol.2008.01.037
Kong, W.-J., Zhang, H., Song, D.-Q., Xue, R., Zhao, W., Wei, J., et al. (2009). Berberine reduces insulin resistance through protein kinase c-dependent up-regulation of insulin. Receptor expression. Metabolism-Clin. Exp. 58, 109–119. doi: 10.1016/j.metabol.2008.08.013
Kunze, A., Huwyler, J., Camenisch, G., and Poller, B. (2014). Prediction of organic anion-transporting polypeptide 1b1-and 1b3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab. Disposition 42, 1514–1521. doi: 10.1124/dmd.114.058412
Lau, C. W., Yao, X. Q., Chen, Z. Y., Ko, W. H., and Huang, Y. (2001). Cardiovascular actions of berberine. Cardiovasc. Drug Rev. 19, 234–244. doi: 10.1111/j.1527-3466.2001.tb00688.x
Lee, T. S., Pan, C. C., Peng, C. C., Kou, Y. R., Chen, C. Y., Ching, L. C., et al. (2010). Anti-atherogenic effect of berberine on krtn-abc1-dependent cholesterol efflux in macrophages. J. Cell. Biochem. 111, 104–110. doi: 10.1002/jcb.22667
Li, J., Wang, Y., Zhang, W., Huang, Y., Hein, K., and Hidalgo, I. J. (2012). The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems. *Drug Metab. Disposition* 40, 2102–2108. doi: 10.1124/dmd.112.045666

Li, G., Zhao, M., Qiu, F., Sun, Y., and Zhao, L. (2019). Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: An open-label, randomized, parallel study in healthy Chinese subjects. *Drug Design Dev. Ther.* 13, 129–139. doi: 10.2147/dddt.s185487

Mak, P. A., Kast-Weibenhöft, H. R., Anisfeld, A. M., and Edwards, P. A. (2002). Identification of pltp as an lxr target gene and apoe as an fxr target gene reveals overlapping targets for the two nuclear receptors. *J. Lipid Res.* 43, 2037–2041. doi: 10.1194/jlr.C200014-JLR200

Meyer Zu Schwabedissen, H. E., Böttcher, K., Chaudhry, A., Kroemer, H. K., Mak, P. A., Kast-Woelbern, H. R., Anisfeld, A. M., and Edwards, P. A. (2002). Overlapping targets for the two nuclear receptors. *IUBMB Life* 43, 2037–2041. doi: 10.1002/hep.23876

Montes, F. Q., Vázquez-Hernández, A., and Fenton-Navarro, B. (2019). Active compounds of medicinal plants, mechanism for antioxidant and beneficial effects. *Phytotn Int. J. Exp. Bot.* 88, 1–10. doi: 10.32604/phyton.2019.04525

Neag, M. A., Mocan, A., Echeverría, J., Pop, R. M., Bocsan, C. I., Crișan, G., et al. (2018). Berberine: Botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. *Front. Pharmacol.* 9, 557. doi: 10.3389/fphar.2018.00557

Peet, D. J., Turley, S. D., Ma, W. Z., Janowski, B. A., Lobaccaro, J. M. A., Hammer, R. E., et al. (1998). Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor lxr alpha. *Cell* 93, 693–704. doi: 10.1016/s0092-8674(00)81432-4

Robinson, J. G., and Davidson, M. H. (2006). Combination therapy with exetimibe and simvastatin to achieve aggressive ldl reduction. *Expert Rev. Cardiovasc. Ther.* 4, 461–476. doi: 10.1586/14779072.4.4.461

Ruan, H., Zhan, Y., Hou, J., Xu, B., Chen, B., Tian, Y., et al. (2017). Berberine binds rxrα to suppress β-catenin signaling in colon cancer cells. *Oncoene* 36, 6906. doi: 10.1038/onc.2017.296

Schmitt, G., and Langmann, T. (2001). Structure, function and regulation of the abc1 gene product. *Curr. Opin. Lipidol.* 12, 129–140. doi: 10.1097/00014433-200104000-00006

Shitara, Y., and Sugiyama, Y. (2006). Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. *Pharmacol. Ther.* 112, 71–105. doi: 10.1016/j.pharmthera.2006.03.003

Staffa, J. A., Chang, J., and Green, L. (2002). Cerivastatin and reports of fatal rhabdomyolysis. *New Engl. J. Med.* 346, 539–540. doi: 10.1056/nejm2002022143460721

Staudinger, J. L., Woody, S., Sun, M., and Cui, W. (2013). Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver. *Drug Metab. Rev.* 45, 48–59. doi: 10.3109/03602532.2012.748793

Sugatani, J., Hattori, Y., Noguchi, Y., Yamaguchi, M., Yamazaki, Y., and Ikari, A. (2014). Theorenone-290 regulates nuclear translocation of the human pregnane x receptor through its phosphorylation/dephosphorylation by ca2+/calmodulin-dependent protein kinase ii and protein phosphatase 1. *Drug Metab. Disposition* 42, 1708–1718. doi: 10.1124/dmd.114.059139

Urqhart, B. L., Tirona, R. G., and Kim, R. B. (2007). Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs. *J. Clin. Pharmacol.* 47, 566–578. doi: 10.1177/009127007299930

White, C. M. (2002). A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. *J. Clin. Pharmacol.* 42, 963–970. doi: 10.1177/009127002401102876

Wolfe, M. L., Hartman, S. F., Ross, J., L. Bansavich, L. L., Mohler, E. R., Meagher, E., et al. (2001). Safety and effectiveness of niacin when added sequentially to a statin for treatment of dyslipidemia. *Am. J. Cardiol.* 87, 476–47+. doi: 10.1016/s0002-9149(00)01410-7

Xu, W. C., Li, Q., Xin, H. W., Wu, A. R., and Zhong, M. Y. (2005). Effects of berberine on the blood concentration of cyclosporin a in renal transplanted recipients: Clinical and pharmacokinetic study. *Eur. J. Clin. Pharmacol.* 61, 567–572. doi: 10.1007/s00228-005-0952-3

Xu, N., Sanna, L. K., Siow, Y. L., and O, K. (2011). Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia. *Am. J. Physiology-Regulatory Integr. Comp. Physiol.* 300, R635–R643. doi: 10.1152/ajpregu.00441.2010

Xu, W., Lu, C., Zhang, F., Shao, J., and Zheng, S. (2016). Dihydroartemisinin restricts hepatic stellate cell contraction via an fxr-s1pr2-dependent mechanism. *IUBMB Life* 68, 376–387. doi: 10.1002/iub.1492

Yunxin, L., Weiwei, H., Yao, L., Xirui, X., Zheng, Z., Chao, L., et al. (2019). Berberine suppresses colon cancer cell proliferation by inhibiting the scap/sreb1 signaling pathway-mediated lipogenesis. *Biochem. Pharmacol.* 174. doi: 10.1016/j.biocp.2019.113776

Zhong, J., Deng, L., Jiang, Y., Zou, L., Yuan, H., and Tan, S.-X. (2018). Gene expression profiling of hepg(2) cells after treatment with black tea polyphenols. *Biocell* 42, 99–104. doi: 10.32604/biocell.2018.04915

Zhou, T., You, W.-T., Ma, Z.-C., Liang, Q.-D., Tan, H.-L., and C., R. A. (2016). Ginkgolide b protects human umbilical vein endothelial cells against xenobiotic injuries via p38 activation. *Acta Pharmacol. Sin.* 37, 177–186. doi: 10.1038/aps.2015.124

Zhu, X. P., Bian, H., Wang, L., Sun, X. Y., Xu, X., Yan, H. M., et al. (2019). Berberine attenuates nonalcoholic hepatic steatosis through the ampk-srebp-1 signaling pathway. *Free Radical Biol. Med.* 141, 192–204. doi: 10.1016/j.freeradbiomed.2019.06.019

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Liu, Zhu, Wen, Ding, Huang, Xia, Zhang and Xiong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.